Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risk prediction with linked markers: theory

A Rogatko1

  • 1Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.

American Journal of Medical Genetics
|October 23, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis.

Oncogene·2014
Same author

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.

British journal of cancer·2013
Same author

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas.

Sarcoma·2008
Same author

Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients.

Bone marrow transplantation·2004
Same author

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.

Urology·2001
Same author

Patient specific dosing in a cancer phase I clinical trial.

Statistics in medicine·2001
Same journal

Abstracts for the Xth World Congress of Psychiatric Genetics. Brussels, Belgium, 9-13 October 2002.

American journal of medical genetics·2003
Same journal

Defects of blastogenesis.

American journal of medical genetics·2002
Same journal

Malformations of the craniofacial region: evolutionary, embryonic, genetic, and clinical perspectives.

American journal of medical genetics·2002
Same journal

Limb anomalies: Developmental and evolutionary aspects.

American journal of medical genetics·2002
Same journal

Molecular etiology of gut malformations and diseases.

American journal of medical genetics·2002
Same journal

Status of the human malformation map: 2002.

American journal of medical genetics·2002
See all related articles

This study introduces a Bayesian method to predict disease recurrence risks using genetic locus distance and uncertain gene locations. The approach provides updated risk distributions and precision measures for better patient management.

Area of Science:

  • Genetics
  • Biostatistics
  • Medical Informatics

Background:

  • Accurate prediction of disease recurrence risk is crucial for patient management and treatment planning.
  • Existing methods may not fully account for uncertainty in gene locations or utilize distance information effectively.

Purpose of the Study:

  • To develop and present a novel Bayesian methodology for predicting disease recurrence risks.
  • To incorporate genetic locus distance and uncertain gene locations into risk prediction models.
  • To provide a flexible framework for updating risk estimates with new data.

Main Methods:

  • A Bayesian statistical framework was employed to model disease recurrence.
  • The method utilizes distance information between genetic loci.

Related Experiment Videos

  • It explicitly accounts for uncertainty in the precise location of genes.

    • Main Results:

    • The methodology enables the derivation of the posterior distribution of recurrence risks.
    • Point estimates and associated precision measures (e.g., confidence intervals) can be calculated from the posterior distribution.
    • The risk predictions integrate all available location and distance information.

    Conclusions:

    • The proposed Bayesian method offers a robust approach to disease recurrence risk prediction.
    • It provides a more comprehensive risk assessment by considering gene location uncertainty and inter-locus distances.
    • The framework facilitates dynamic updates of risk predictions as new genetic or clinical data emerge.